DOCSLIB.ORG

Biotechnology Stock Project

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biotechnology Stock Project Biotechnology Stock Project You have been given $10,000 to purchase stock in biotech companies. This will be a project that is due at the end of the semester and will start again next semester. Below is a list of biotechnology companies traded on the New York Stock Exchange. You don’t have to use only this list of companies, and you will need to look up each company’s current share cost. You must purchase stock from at least 3 different companies and the maximum is 6 companies. 1. The cost below is for one share. You may purchase as many shares as you like from any one company, remembering that your goal is to make money (See the Trade Column). 2. Each week you must check the stock price from the close of business on Friday of that week. (These are from 8/27/10) 3. You will create a data table and graph that tracks the ups and downs of your investment. 4. For now, just spend your imaginary $10,000 and turn in your list and final amount spent. 5. You’ll need a calculator and the stock purchase worksheet. DON’T GO OVER $10,000! The P/E ratio (price-to-earnings ratio) of a stock is a measure of the price paid for a share relative to the annual net income or profit earned by the firm per share. Name Symbol Trade Change P/E 52-wk Range Previous Close ALSERES PHARMACEUTCL ALSE.PK 0.00 N/A 0.18 - 0.83 0.18 0.18 0.00% Affymetrix, Inc. AFFX 4.21 0.03 0.71% N/A 3.75 - 10.06 4.24 Albany Molecular Research AMRI 0.00 N/A 5.06 - 9.73 6.43 6.43 0.00% ALPHARX INC ALRX.OB 0.05 0.00 0.00% N/A 0.03 - 0.17 0.05 Amgen Inc. AMGN 0.91 10.82 50.32 - 62.52 51.84 50.93 1.76% Anika Therapeutics Inc. ANIK 5.00 0.03 0.60% 15.87 4.83 - 9.25 5.03 ARIAD Pharmaceuticals, Inc. ARIA 0.18 3.51 1.70 - 4.41 3.42 3.24 5.26% AUTOIMMUNE INC AIMM.PK 0.46 0.00 0.00% N/A 0.32 - 0.61 0.46 AVAX TECHS INC AVXT.PK 0.0050 N/A - 0.03 0.03 20.00% BioCryst Pharmaceuticals, Inc. BCRX 4.55 0.12 2.57% N/A 4.43 - 13.47 4.67 Biogen Idec Inc BIIB 1.46 13.72 41.75 - 60.28 55.37 53.91 2.64% BIOMIRA INC BIOM 0.54 0.00 0.00% N/A - 0.54 BIOPURE CORP CL A BPURQ.PK 0.00 N/A 0.01 - 1.28 0.02 0.02 0.00% Cel-Sci Corporation CVM 0.49 0.00 1.01% N/A 0.43 - 2.10 0.50 Cerus Corporation CERS 0.07 N/A 1.57 - 3.71 2.98 2.91 2.35% Covance Inc. Common Stock CVD 38.72 0.55 1.40% 15.37 37.44 - 63.53 39.27 CryoLife, Inc. Common Stock CRY 0.08 16.24 4.80 - 8.87 5.26 5.18 1.52% Cypress Bioscience, Inc. CYPB 3.43 0.29 7.80% N/A 2.06 - 8.37 3.72 CytRx Corporation CYTR 0.05 34.74 0.62 - 1.56 0.71 0.66 7.04% Discovery Laboratories, Inc. DSCO 0.2199 0.0101 4.39% N/A 0.17 - 1.69 0.23 Symbol Trade Change P/E 52-wk Range Previous Close Name Enzon Pharmaceuticals, Inc. ENZN 10.43 0.09 0.86% 3.24 7.05 - 11.60 10.52 GENTA INC GETAD.OB 1.58 0.02 1.25% N/A 1.50 - 126.00 1.60 Genzyme Corporation GENZ 66.84 0.74 1.10% N/A 45.39 - 70.97 67.58 Gilead Sciences, Inc. GILD 32.07 0.75 2.29% 9.72 31.73 - 49.50 32.82 Heska Corporation HSKA 0.44 0.01 2.22% 31.43 0.36 - 1.08 0.45 IGI, Laboratories Inc. Common S IG 1.33 0.00 0.00% N/A 0.21 - 1.50 1.33 Incyte Corporation INCY 11.83 0.31 2.55% N/A 5.30 - 14.98 12.14 Integra LifeSciences Holdings C IART 35.29 0.31 0.87% 17.41 29.69 - 46.73 35.60 LA JOLLA PHARMA LJPC.PK 0.0390 0.0010 2.50% N/A 0.03 - 0.32 0.04 Martek Biosciences Corporation MATK 21.20 0.16 0.75% 16.83 17.09 - 25.43 21.36 Myriad Genetics, Inc. MYGN 15.10 0.54 3.45% 9.83 14.11 - 31.95 15.64 Nabi Biopharmaceuticals NABI 4.86 0.05 1.02% N/A 2.97 - 6.42 4.91 NORTH AMERN SCI NASMQ.PK 0.0011 0.00 0.00% N/A 0.01 - 0.47 0.00 NPS Pharmaceuticals, Inc. NPSP 5.90 0.28 4.53% N/A 2.84 - 7.75 6.18 ONYX Pharmaceuticals, Inc. ONXX 24.85 0.42 1.66% N/A 19.54 - 35.67 25.27 OXiGENE, Inc. OXGN 0.2980 0.0004 0.13% N/A 0.27 - 1.75 0.30 PANACOS PHARMA INC PANC.PK 0.0070 0.0010 12.50% N/A 0.01 - 0.04 0.01 PROGEN PHARMACEUTICL PGLA.PK 0.25 0.04 13.79% N/A 0.18 - 0.68 0.29 PDL BioPharma, Inc. PDLI 5.54 0.03 0.54% 6.63 4.97 - 9.32 5.51 Qiagen N.V. QGEN 17.79 0.04 0.22% 26.95 17.56 - 24.00 17.83 Regeneron Pharmaceuticals REGN 21.84 0.63 2.80% N/A 15.02 - 30.58 22.47 Repligen Corporation RGEN 3.40 0.11 3.13% N/A 3.00 - 5.33 3.51 Repros Therapeutics Inc. RPRX 0.58 0.02 3.33% N/A 0.28 - 2.48 0.60 TARGETED GENETICS CP TGEN.PK 0.40 0.01 2.44% 1.03 0.13 - 0.60 0.41 Techne Corporation TECH 58.25 0.34 0.58% 19.82 55.63 - 69.95 58.59 TITAN PHARMA INC TTNP.OB 0.93 0.01 1.09% N/A 0.90 - 2.49 0.92 Vical Incorporated VICL 3.02 0.08 2.58% N/A 2.66 - 5.51 3.10 VION PHARMACEUTICALS VIONQ.OB 0.07 0.00 0.00% N/A 0.04 - 6.54 0.07 ViroPharma Incorporated VPHM 12.52 0.06 0.48% 12.25 7.28 - 14.40 12.58 XOMA Ltd. XOMAD 2.63 0.06 2.23% N/A 0.25 - 3.65 2.69 Information from the following websites on 8/27/10: http://www.pharmcast.com/StockQuotes/BiotechAtoCVer3.htm, http://www.pharmcast.com/StockQuotes/BiotechDtoMVer3.htm, http://www.pharmcast.com/StockQuotes/BiotechNtoZVer3.htm, http://www.profitquotes.com/biotech-stocks-list/ (2015 Resource) .
Load more

Recommended publications
  • By in Vivo's Biopharma, Medtech and Diagnostics Teams
    invivo.pharmaintelligence.informa.com JANUARY 2018 Invol. 36 ❚ no. 01 Vivopharma intelligence ❚ informa 2018 OUTLOOK By In Vivo’s Biopharma, Medtech and Diagnostics Teams PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | January 2018 BIOPHARMA MEDTECH 2018 DIAGNOSTICS OUTLOOK 12 22 28 Biopharma 2018: Medtech 2018: Diagnostics 2018: Is There Still A Place For Pharma The Place For Innovation Steady Progress And In The New Health Care As Value-based Health Care The Big Get Bigger Economy? Gains Momentum MARK RATNER WILLIAM LOONEY ASHLEY YEO If the beginning of 2017 was marked 2018 will be a time of transition in health 2017 was a watershed year in many by doubts around whether and how care, when biopharma’s counterparts respects, politically, economically the FDA would act with respect to in adjacent industry segments scale up and commercially for many players complex diagnostics, we enter 2018 in a radical redesign of their traditional in the medtech field. Where will the feeling that slow-moving vessel may business models. Biopharma is not opportunities lie in 2018? Will finally be turning. moving as quickly, and it confronts a breakthrough medtech innovation still strategic dilemma on how to address the have a place among providers often prospect of a much more powerful set of riding on fumes when it comes to 36 rivals in the ongoing battle to own the budgets, and is it all as bad as some patient experience in medicine. would make out? Thirty-five Years Covering Health Care: The More Things Change… 30 PETER CHARLISH A Virtuous Cycle: What The The health care industry has come a Immuno-Oncology Revolution long way in the past 35 years, although Means For Other Disease Areas in some areas very little has changed.
    [Show full text]
  • Symbols Alexian Brothers Health System Index to Nov P
    Volume 19, Index December 2014 Symbols Alexian Brothers Health System Index to Nov p. 2 Health Care M&A News 1-800-CONTACTS Feb p. 18 A&L Goodbody Apr p. 16, July p. 16 All Care Home Health, LLC Feb p. 17 Each company and orga- A Allergan Inc. Feb p. 10, May p. 1, nization discussed in Health May p. 19, Jun p. 15, July p. 3, Care M&A News, from Janu- Abbott Labs July p. 3, Aug p. 17, July p. 10, Sept p. 16, Oct p. 3, ary through December 2014, Dec p. 4 Nov p. 1, Dec p. 4, Dec p. 16, is listed alphabetically here. AbbVie Inc. July p. 3, July p. 16, Dec p. 19 References are typically to Aug p. 9, Oct p. 2, Oct p. 16, Allscripts Feb p. 2, Apr p. 10 the first occurrence of the Nov p. 19, Dec p. 2 AllSpire Health Partners Nov p. 2 company’s or organiza- ABL, Inc. Aug p. 18 All Staffing Services Jan p. 17 tion’s name in the pertinent Acadia Healthcare Company Feb p. 16, Almost Family, Inc. Apr p. 16 issue; further discussion July p. 17, Oct p. 17, Nov p. 17 ALN Medical Management, LLC may follow later in the text Accelera Innovations, Inc. Jan p. 17 Accelrys, Inc. Jan p. 15 Feb p. 8 but is not indicated here. AccessClosure, Inc. May p. 15 Alta Partners Jun p. 16 Achillion Pharmaceuticals July p. 17 Altos Solutions, Inc. Jun p. 15 References are sorted by Actavis (Foshan) Pharmaceuticals Co.
    [Show full text]
  • Preclinical Development & IND Filing: Nuts, Bolts, Best Practices
    “Preclinical Development & IND Filing: Nuts, Bolts, Best Practices and Regulatory Aspects.” Speakers: Amit Kalgutkar (Pfizer), Chandra Prakash (Agios), Sanjeev Thohan (Novartis), Li- Chun Wang (Takeda), Wei Yin (Biogen) Organizers: Sanjeev Thohan and Chandra Prakash Date: 6/29/2017 Time: 8:30 am – 5.00 pm Location: Boston/Cambridge Area: Marriott Kendall Square, 50 Broadway, Cambridge MA 02142 Fees: $175 - Regular (before June 1st, 2017), $225 - Regular (after June 1st, 2017); $125 - Unemployed & Academic; $2000 - Major Sponsorship; $475 - Vendor Show Registration: www.PBSS.org Workshop Description: An investigational new drug application (IND) is an important milestone that marks the entry of a molecule into clinical development. Knowing the objectives, expectations and processes of assembling an IND is a key to not only successful filing, but also a promising clinical development path forward. Often there are cases where too many of our “nice-to-have” studies crowd the package at the expense of critical study needs/issues. This can lead to significant delays in clinical developments with back-and-forth of Q&A sessions both internally and with regulatory agencies. As we have seen, the regulatory landscape is changing as rapidly as the industry innovates into new therapeutic modalities. Therefore, it is critical to keep up to date on regulatory requirements and the industry’s best practices in different aspects of the IND: non- clinical safety, PK, CMC, and clinical plans. In this workshop, our speakers who bring years of experience with multiple successful IND filings, will discuss systematically the preclinical studies required for small molecule IND’s as well as the nuts and bolts of putting together a high–quality IND package.
    [Show full text]
  • Healthcare & Life Sciences Group
    HEALTHCARE & LIFE SCIENCES GROUP 2 1 Healthcare and life sciences clients have long turned to S&C for help succeeding in today’s rapidly changing business environment. Large and mid-size, public and private, throughout their lifecycles, these companies rely on our multi-disciplinary, global team to address their most complex legal and business challenges and reach their strategic goals. Sector expertise: We offer unrivaled OUR CLIENTS GET… knowledge of the healthcare and life sciences industries, our clients’ businesses and the sector-specific competitive pressures bearing down on them. Sullivan & Cromwell’s Healthcare and Life Sciences Group has negotiated complex transactions and resolved high-stakes disputes for almost three decades. Today, it possesses an unparalleled grasp of these sectors and a practical understanding of the commercial realities underlying them. We position our clients to succeed through it all. The Firm represents international clients in the following healthcare sectors: Pharmaceuticals and Life Sciences Medtech Health Insurers Healthcare Services 2 Legal expertise: Clients come to us An integrated, global team: for the high-quality counsel and hands-on We’re a core group of dedicated healthcare representation we offer across multiple advisers across our 13 offices on four legal specialties, to successfully execute continents with a strong track record of their most important deals and resolve the sector’s most significant transactions critical disputes. We can execute any type and litigation matters, supported by all of transaction in any economic climate or the resources of an integrated, global firm. geographic region. Our experience in this We’re grateful to our clients for trusting sector includes: us with their future, and we’ll continue to help them position themselves for growth M&A and success in this exciting and ever- Corporate finance changing industry.
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • February 11-12, 2013 the Waldorf Astoria New York
    February 11-12, 2013 The Waldorf Astoria New York 15th ANNU AL EVENT Now in its fifteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. Reasons Top 10 to attend 1 Present your company story to an audience of targeted investors. 2 Hear the Washington perspective on the Affordable Care Act, debt ceiling, and other timely policy developments affecting the industry. 3 Evaluate fresh investment opportunities including compatible, complementary and competitive companies. 4 Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables. 5 Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013. 6 Gain access to BIO’s 1x1 Partnering System for scouting potential deal partners and optimizing your time at the event. 7 Access presentations from more than 140 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences. 8 Get the pulse on the current and proposed investment trends in biotechnology. 9 Network with peers, investors and potential partners attending the conference. 10 It’s the first NYC biotech conference of the year, kicking off a week of key industry events that you don’t want to miss.
    [Show full text]
  • CDER – Redi: Focus on CGMP & FDA Inspections – Participant List
    FDA – CDER – RedI: Focus on CGMP & FDA Inspections – Participant List These participants granted permission to share their contact information Eileen Zhou Michael Channing A B M Mahfuz ul Alam Research Associate Group Chief - Positron Emission General Manager, Quality Operations Neuralstem Tomography Department ACI HealthCare Limited Germantown, MD, United States NIH Dhaka, Non-US, Bangladesh [email protected] Bethesda, MD, United States [email protected] [email protected] Abe Wong ABHIJEET GUJAR Adam Ebbinghouse CCO Chief Operating Officer QC Associate Gmpsigma SETHU KP Pharmaceutical Technology, Inc. Seattle, WA, United States Porvorim Goa, Non-US, India Bloomington, IN, United States [email protected] [email protected] [email protected] Adil Gatrad Adiseshu Modugula Aditiben Patel Director, Quality Systems RA Regulatory Specialist Actavis MSN USAMMDA Parsippany, NJ, United States Hyderabad, Non-US, India Frederick, MD, United States [email protected] [email protected] [email protected] Adriana de la Cruz ahsanul haque Aimee Gogarty Manager CSO Quality Coordinator Laboratorios Pisa SA de CV FDA Mallinckrodt Jalisco, Non-US, Mexico silver spring, MD, United States Port Allen, LA, United States [email protected] [email protected] [email protected] Aislyn Fronzak Ajay Deshmukh Ajay Khedkar QC Manager QA manager Regulatory Affair PL Developments Ingenus Pharmaceutical Umedica Laboratories Pvt Ltd Clinton, SC, United States Navi mumbai, Non-US, India Mumbai, Non-US, India [email protected]
    [Show full text]
  • PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS O REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 De Agosto De 2008
    PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS o REVISTA DA PROPRIEDADE INDUSTRIAL N 1964 26 de Agosto de 2008 SEÇÃO I REPÚBLICA FEDERATIVA DO BRASIL Presidente Luís Inácio Lula da Silva MINISTÉRIO DO DESENVOLVIMENTO, INDÚSTRIA E COMÉRCIO EXTERIOR Ministro do Desenvolvimento, Indústria e Comércio Exterior Miguel João Jorge Filho INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL PRESIDENTE PARANÁ Jorge de Paula Costa Ávila Chefe: Renee Fernando Senger Pernambuco Rua Marechal Deodoro, 344, 16º andar Universitária Federal de Pernambuco - UFPE VICE-PRESIDENTE Ademir Tardelli Edifício Atalaia, Centro, Curitiba - PR Av. Prof. Moraes Rego, 1235 – Campus Universitário CEP: 80010-909 Bairro - Engenho do Meio CHEFE DE GABINETE Telefone/Fax: (0XX-41) 3322-4411 Recife - PE - CEP: 50670-920 Josefina Sales de Oliveira RIO GRANDE DO SUL Tel/Fax:(0XX-81) 3453-8145 e 3271-1223 Chefe: Vera Lúcia de Seixas Grimberg Piauí DIRETORIA DE ARTICULAÇÃO E INFORMAÇÃO TECNOLÓGICA Rua Sete de Setembro, 515 – 5º andar - Centro Av. João XXIII, n° 865 Marco Antônio Lima Porto Alegre - RS - CEP: 90010-190 Espaço Cidadania Telefone/Fax.: (0XX-51) 3226-6909 e 3226-6422 Teresina - PI - CEP: 64049-010 PROCURADORIA GERAL SÃO PAULO Tel.:(0XX-86) 3235-9616/3218-1838 Mauro Sodré Maia Chefe: Maria dos Anjos Marques Buso Fax:(0XX-86) 3218-1838 DIRETORIA DE PATENTES Rua Tabapuã, 41 - 4º andar - Itaim-Bibi Rio Grande do Norte Carlos Pazos Rodrigues São Paulo - SP - CEP: 04533-010 SECRETÁRIA DO DESENVOLVIMENTO ECONÔMICO – DIRETORIA DE MARCAS Telefone/Fax:
    [Show full text]
  • Stamford Therapeutics Consortium Consortiapedia.Fastercures.Org
    Stamford Therapeutics Consortium consortiapedia.fastercures.org Stamford Therapeutics Consortium consortiapedia.fastercures.org/consortia/stamford-therapeutics-consortium/ Research Areas At a Glance Status: Active Consortium Tool Development Year Launched: 1994 Clinical Trial Initiating Organization: Dr. Paul Dalgin Data-Sharing Enabler Initiator Type: Industry Location: North America DevelopmentProduct Drugs Abstract Stamford Therapeutics Consortium (STC) is a privately owned and operated clinical research site specializing in phase II, III, and IV clinical trials for the pharmaceutical and biotechnology industries. STC has a strong working relationship with a cardiology group, a large multispecialty medical practice, and a team of physicians who serve as sub-investigators for many of its clinical trials. STC maintains a significant presence in research for the treatment of osteoarthritis and rheumatoid arthritis, while continuing to expand its research into new therapeutic areas. Year after year STC's list of specialties grows to accommodate a growing demand and new innovations in healthcare. With over 15 years of clinical trials operations, STC has conducted more than 350 national and multi-national clinical trials. Mission The company’s sole mission is to conduct the highest quality clinical trials so that new, safe, and effective medications can be developed, researched, and approved for a variety of indications and diseases. Stamford Therapeutics Consortium - consortiapedia.fastercures.org Page 1/4 Stamford Therapeutics Consortium consortiapedia.fastercures.org Consortium History The site was launched in 1994 and has contributed to clinical trials research ever since. Structure & Governance The consortium is governed by their president, medical director, founder, and clinical research coordinators. Patent Engagement STC actively recruits patients from all over Fairfield County, CT and Westchester County, NY.
    [Show full text]
  • Bristol-Myers Squibb Company [email protected]
    UNITED STATES SECURITIES A ND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE March 1, 2019 Lisa A. Atkins Bristol-Myers Squibb Company [email protected] Re: Bristol-Myers Squibb Company Incoming letter dated December 21, 2018 Dear Ms. Atkins: This letter is in response to your correspondence dated December 21, 2018 concerning the shareholder proposal (the “Proposal”) submitted to Bristol-Myers Squibb Company (the “Company”) by People for the Ethical Treatment of Animals (the “Proponent”) for inclusion in the Company’s proxy materials for its upcoming annual meeting of security holders. We also have received correspondence from the Proponent dated January 3, 2019. Copies of all of the correspondence on which this response is based will be made available on our website at http://www.sec.gov/divisions/corpfin/ cf-noaction/14a-8.shtml. For your reference, a brief discussion of the Division’s informal procedures regarding shareholder proposals is also available at the same website address. Sincerely, M. Hughes Bates Special Counsel Enclosure cc: Jared Goodman PETA Foundation [email protected] March 1, 2019 Response of the Office of Chief Counsel Division of Corporation Finance Re: Bristol-Myers Squibb Company Incoming letter dated December 21, 2018 The Proposal asks the board to implement a policy that it will not fund, conduct or commission use of the “Forced Swim Test.” There appears to be some basis for your view that the Company may exclude the Proposal under rule 14a-8(i)(7), as relating to the Company’s ordinary business operations. In our view, the Proposal micromanages the Company by seeking to impose specific methods for implementing complex policies.
    [Show full text]
  • Second-Quarter Biotech Job Picture
    CAREERS AND RECRUITMENT Second-quarter biotech job picture Michael Francisco n May, Merck (Kenilworth, NJ, USA) announced it would invest $310 investment capital. The first 13 life science companies in residence were Imillion over the next three years to expand two sites in Ireland—a announced, eight of which are focused on therapeutics and drug discov- biologics facility in Brinny, County Cork, and a vaccines and biologics ery: aratinga.bio, Chimeron Bio, Hookipa Biotech, ENB Therapeutics, plant in Carlow Town, County Carlow—with plans to add 330 jobs in Beagle Bioscience, Sevengenes, Gotham Therapeutics and Renovo total. The Carlow facility is a key production site for the cancer drug Pharmaceuticals. Keytruda (pembrolizumab), which was recently approved by the US And Lexington, Massachusetts–based Agenus said it will shutter its Food and Drug Administration. Just last year, the drugmaker said it site in Basel, Switzerland, and consolidate operations to Cambridge, would add 110 jobs at its plant in Carlow and another 50 positions to UK, and Lexington, as well as focus on its manufacturing operations its operations in Cork. in Berkeley, California. The company will reduce head count by about Last month saw the opening of Alexandria LaunchLabs in the 50 employees. Alexandria Center for Life Science in New York City, as part of a Advertised biotech and pharmaceutical sector jobs in the job data- nearly $1.2-billion joint effort by the city and state of New York to spur bases tracked by Nature Biotechnology during the second quarter of development in the life sciences. LaunchLabs is designed to provide 2017 are shown in Tables 1 and 2.
    [Show full text]
  • JMP Securities Healthcare Conference to Be Held in New York
    JMP Securities Healthcare Conference to Be Held in New York SAN FRANCISCO, Oct 01, 2008 (BUSINESS WIRE) -- JMP Group Inc. (NYSE:JMP), an investment banking and alternative asset management firm, announced today that its broker-dealer subsidiary, JMPSecurities, will host the third annual JMP Securities Healthcare Focus Conference at Le Parker Meridien in New York on Monday and Tuesday, October 6 and 7, 2008. The two-day conference will feature presentations by senior executives of nearly 90 public and private companies in the biotechnology, medical devices and healthcare services industries before an audience of institutional investors and financial sponsors. For additional details or to register to attend the event, visit www.jmpsecurities.com/about/events.html or www.twstevent.com/jmp.html. Companies scheduled to present as of September 30, 2008; subject to change: A.D.A.M., Inc. ACADIA Pharmaceuticals Inc. Acceleron Pharma, Inc. Achillion Pharmaceuticals, Inc. Alexza Pharmaceuticals, Inc. Allos Therapeutics, Inc. Allscripts Healthcare Solutions, Inc. Alnylam Pharmaceuticals, Inc. American CareSource Holdings, Inc. Anadys Pharmaceuticals, Inc. ARCA biopharma, Inc. Ardea Biosciences, Inc. athenahealth Inc. AtriCure, Inc. AVEO Pharmaceuticals, Inc. AVI BioPharma, Inc. BioCryst Pharmaceuticals, Inc. C. R. Bard, Inc. Cadence Pharmaceuticals, Inc. Celera Corporation Celgene Corporation Celleration, Inc. Cerus Corporation Chem Rx Corporation Concert Pharmaceuticals, Inc. Corcept Therapeutics Incorporated Cypress Bioscience, Inc. Cytokinetics, Incorporated DexCom, Inc. DiagnoCure Inc. Dialysis Corporation of America Echo Therapeutics, Inc. Eclipsys Corp. Enanta Pharmaceuticals, Inc. Endocare Inc. Exelixis, Inc. EyeGate Pharmaceuticals, Inc. Genomic Health, Inc. Given Imaging, Ltd. HeartWare Limited Horizon Therapeutics, Inc. Human Genome Sciences, Inc. HydroCision, Inc. Idenix Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc.
    [Show full text]